SCHEMBL21977192

SCHEMBL21977192

Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1C(=O)c1c[nH]c2ncccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 2/20 0.43
▸ PDGFRB P09619 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ KIT P10721 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ FLT3 P36888 1/20 0.43
▸ PTK6 Q13882 1/20 0.43
▸ MAP2K1 Q02750 1/20 0.40
▸ CDK2 P24941 11/20 0.37
▸ CCNE1 P24864 9/20 0.37
▸ KDR P35968 1/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ CSNK1E P49674 1/20 0.35
▸ BRAF P15056 1/20 0.35
▸ CCNT1 O60563 2/20 0.34
▸ CCNA2 P20248 2/20 0.34
▸ CDK9 P50750 2/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21873079 0.87 CSF1R (0.43) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL21872995 0.83 CSF1R (0.48) CSF1RPDGFRBPDGFRAFLT3MAP2K1
SCHEMBL21873003 0.81 GPR84 (0.45) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL21873044 0.80 CDK2 (0.39) CYP2C9FLT3MAP2K1CDK2CCNE1
SCHEMBL21872991 0.80 MAP2K1 (0.43) MAP2K1CDK2CCNE1KDRBRAF
SCHEMBL28339596 0.79 CSF1R (0.44) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL29222872 0.74 CSF1R (0.54) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL30825676 0.74 CSF1R (0.54) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL21873037 0.72 CSF1R (0.43) CSF1RPDGFRBLCKKITCYP2C9
SCHEMBL21872971 0.71 CSF1R (0.53) CSF1RPDGFRBLCKKITCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885LCK 2779/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885LCK 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback